• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Nanoray-312：NBTXR3联合放疗±西妥昔单抗治疗老年、铂类不适用的局部晚期头颈部鳞状细胞癌的III期研究。

Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC.

作者信息

Le Tourneau Christophe, Takácsi-Nagy Zoltán, Nuyts Sandra, Thureau Sébastien, Liu Feng, Hoffmann Caroline, Hackman Trevor G, Lesnik Maria, Debard Anaïs, Finzi Laetitia, Devisetty Kiran, Vivar Omar I, Farber Leonard A, Nguyen France, Liem Xavier, Natelauri Eteri, Psyrri Amanda, Burian Martin, Yu Jinming, Yom Sue S

机构信息

Department of Drug Development and Innovation (D3I), Institut Curie, Paris, France.

Center of Radiotherapy and National Tumorbiology Laboratory, National Institute of Oncology and Department of Oncology, Semmelweis University, Budapest, Hungary.

出版信息

Future Oncol. 2025 May;21(12):1489-1499. doi: 10.1080/14796694.2025.2496131. Epub 2025 May 5.

DOI:10.1080/14796694.2025.2496131
PMID:40323213
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12077427/
Abstract

https://clinicaltrials.gov identifier is NCT04892173; EudraCT Number: 2021-002163-22.

摘要

美国国立医学图书馆临床试验注册中心标识符为NCT04892173；欧盟临床试验数据库编号：2021-002163-22。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b362/12077427/b1e72a135cbb/IFON_A_2496131_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b362/12077427/b1e72a135cbb/IFON_A_2496131_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b362/12077427/b1e72a135cbb/IFON_A_2496131_F0001_OC.jpg

相似文献

1
Nanoray-312: phase III study of NBTXR3 + radiotherapy ± cetuximab in elderly, platinum-ineligible locally advanced HNSCC.Nanoray-312：NBTXR3联合放疗±西妥昔单抗治疗老年、铂类不适用的局部晚期头颈部鳞状细胞癌的III期研究。
Future Oncol. 2025 May;21(12):1489-1499. doi: 10.1080/14796694.2025.2496131. Epub 2025 May 5.
2
Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx.NBTXR3 联合强度调制放疗治疗老年局部晚期口腔或口咽鳞癌的 I 期剂量递增研究。
Eur J Cancer. 2021 Mar;146:135-144. doi: 10.1016/j.ejca.2021.01.007. Epub 2021 Feb 16.
3
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.西妥昔单抗或度伐利尤单抗用于顺铂禁忌的局部晚期头颈癌患者的放疗（NRG-HN004）：一项开放标签、多中心、平行组、随机、2/3期试验。
Lancet Oncol. 2024 Dec;25(12):1576-1588. doi: 10.1016/S1470-2045(24)00507-2. Epub 2024 Nov 14.
4
Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review.局部晚期头颈部鳞状细胞癌铂类药物不耐受患者的治疗选择：系统评价。
J Cancer Res Clin Oncol. 2024 Aug 2;150(8):379. doi: 10.1007/s00432-024-05887-z.
5
nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial.白蛋白结合型紫杉醇联合顺铂化疗序贯顺铂和放疗（Arm1）与白蛋白结合型紫杉醇联合西妥昔单抗和放疗（Arm2）治疗局部晚期头颈部鳞状细胞癌：一项多中心、非随机的 2 期临床试验。
Med Oncol. 2021 Mar 8;38(4):35. doi: 10.1007/s12032-021-01479-w.
6
Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).avelumab-西妥昔单抗-放疗与头颈部局部晚期鳞状细胞癌的标准治疗比较：GORTEC 2017-01（REACH）随机 III 期试验的安全性阶段。
Eur J Cancer. 2020 Dec;141:21-29. doi: 10.1016/j.ejca.2020.09.008. Epub 2020 Oct 24.
7
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.NBTXR3，一种首创的放射性增敏剂氧化铪纳米颗粒，联合放射治疗对比单纯放射治疗用于局部晚期软组织肉瘤患者（Act.In.Sarc）：一项多中心、2-3 期、随机、对照临床试验。
Lancet Oncol. 2019 Aug;20(8):1148-1159. doi: 10.1016/S1470-2045(19)30326-2. Epub 2019 Jul 8.
8
Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review & meta-analysis.顺铂不耐受的头颈部鳞状细胞癌患者同步免疫治疗与放疗：一项系统评价与荟萃分析
Immunotherapy. 2024;16(20-22):1227-1233. doi: 10.1080/1750743X.2024.2436346. Epub 2024 Dec 6.
9
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.顺铂联合西妥昔单抗同期放化疗治疗头颈部鳞状细胞癌：退伍军人事务部数据分析。
Cancer. 2019 Feb 1;125(3):406-415. doi: 10.1002/cncr.31816. Epub 2018 Oct 20.
10
A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.一项在 III-IVB 期头颈部鳞状细胞癌中同步进行西妥昔单抗和 BYL719（阿培利司）与调强放疗的 1b 期研究。
Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):564-570. doi: 10.1016/j.ijrobp.2019.09.050. Epub 2019 Oct 31.

引用本文的文献

1
ROS-Responsive Nanoplatforms for Targeted Tumor Immunomodulation: A Paradigm Shift in Precision Cancer Immunotherapy.用于靶向肿瘤免疫调节的ROS响应性纳米平台：精准癌症免疫治疗的范式转变
Pharmaceutics. 2025 Jul 5;17(7):886. doi: 10.3390/pharmaceutics17070886.

本文引用的文献

1
The Emerging Role of Nanoparticles Combined with Either Radiotherapy or Hyperthermia in Head and Neck Cancer: A Current Review.纳米颗粒联合放疗或热疗在头颈癌中的新兴作用：当前综述
Cancers (Basel). 2025 Mar 6;17(5):899. doi: 10.3390/cancers17050899.
2
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.西妥昔单抗或度伐利尤单抗用于顺铂禁忌的局部晚期头颈癌患者的放疗（NRG-HN004）：一项开放标签、多中心、平行组、随机、2/3期试验。
Lancet Oncol. 2024 Dec;25(12):1576-1588. doi: 10.1016/S1470-2045(24)00507-2. Epub 2024 Nov 14.
3
International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers.
头颈部癌症中 NBTXR3 纳米颗粒瘤内和瘤内注射的国际指南。
Head Neck. 2024 Jun;46(6):1253-1262. doi: 10.1002/hed.27739. Epub 2024 Apr 10.
4
Radiotherapy-activated NBTXR3 nanoparticles promote ferroptosis through induction of lysosomal membrane permeabilization.放疗激活的 NBTXR3 纳米颗粒通过诱导溶酶体膜通透性促进铁死亡。
J Exp Clin Cancer Res. 2024 Jan 3;43(1):11. doi: 10.1186/s13046-023-02938-0.
5
A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Chemoradiation.不同化疗方案在接受根治性放化疗的老年头颈部鳞状细胞癌患者中的多中心评估
Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1282-1293. doi: 10.1016/j.ijrobp.2023.10.025. Epub 2023 Oct 31.
6
Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?管理经顺铂治疗无效的、经手术切除的、高危、局部晚期头颈部鳞状细胞癌患者：是否存在标准治疗方法？
Cancer Treat Rev. 2023 Sep;119:102585. doi: 10.1016/j.ctrv.2023.102585. Epub 2023 Jun 15.
7
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.头颈部癌症患者中多西他赛作为放射增敏剂的 III 期随机试验结果，不适合顺铂为基础的放化疗。
J Clin Oncol. 2023 May 1;41(13):2350-2361. doi: 10.1200/JCO.22.00980. Epub 2023 Jan 27.
8
Eligibility criteria to cisplatin in head and neck squamous cell carcinoma: Egyptian expert opinion.头颈部鳞状细胞癌中顺铂的适用标准：埃及专家意见
Health Sci Rep. 2023 Jan 18;6(1):e1037. doi: 10.1002/hsr2.1037. eCollection 2023 Jan.
9
Treatment Considerations for Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin.局部晚期头颈部癌症且对顺铂有禁忌证的患者的治疗注意事项。
Curr Treat Options Oncol. 2023 Mar;24(3):147-161. doi: 10.1007/s11864-023-01051-w. Epub 2023 Jan 25.
10
Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects.头颈部鳞状细胞癌的免疫调节治疗：最新进展和临床前景。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221150559. doi: 10.1177/15330338221150559.